Patents by Inventor Kirsten Alison Rinderspacher

Kirsten Alison Rinderspacher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
    Patent number: 11261199
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: March 1, 2022
    Assignees: The Trustees of Columbia University in the City of New York, NY State Psychiatric Institute
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
    Patent number: 11230558
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: January 25, 2022
    Assignees: The Trustees of Columbia University in the City of New York, NY State Psychiatric Institute
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
    Patent number: 11008341
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: May 18, 2021
    Assignees: The Trustees of Columbia University in the City of New York, NY State Psychiatric Institute
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • TRIAZOLOPYRIMIDINES, THEIR PREPARATION AND USE
    Publication number: 20210047337
    Abstract: The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3, C1-C4 alkyl, aryl or heteroaryl; X is N or CR6, wherein R6 is H, OH, or halogen; A is absent or present, and when present is B has the structure: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 30, 2020
    Publication date: February 18, 2021
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Konstantin Petrukhin, Kirsten Alison Rinderspacher, Shi-Xian Deng, Andras Varadi, Boglarka Racz, Peter Bernstein, Patricia C. Weber, Donald W. Landry, Andrew S. Wasmuth
  • Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
    Patent number: 10865214
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: December 15, 2020
    Assignees: The Trustees of Columbia University in they City of New York, NY State Psychiatric Institute
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
    Publication number: 20200216469
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 9, 2020
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
    Patent number: 10626124
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: April 21, 2020
    Assignees: The Trustees of Columbia University in the City of New York, NY State Psychiatric Institute
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
    Patent number: 10487091
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: November 26, 2019
    Assignees: The Trustees of Columbia University in the City of New York, NY State Psychiatric Institute
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
    Publication number: 20190112317
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Application
    Filed: October 5, 2016
    Publication date: April 18, 2019
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
    Publication number: 20180319818
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 8, 2018
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
    Publication number: 20180312527
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 1, 2018
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
    Publication number: 20180312526
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 1, 2018
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE
    Publication number: 20180305314
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Application
    Filed: June 26, 2018
    Publication date: October 25, 2018
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Donald W. Landry, Yuli Xie, Yidong Liu, Gangli Gong, Shi-Xian Deng, Kirsten Alison Rinderspacher
  • Potent non-urea inhibitors of soluble epoxide hydrolase
    Patent number: 10005732
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: June 26, 2018
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Donald W. Landry, Yuli Xie, Yidong Liu, Gangli Gong, Shi-Xian Deng, Kirsten Alison Rinderspacher
  • ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
    Publication number: 20170210759
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Application
    Filed: April 5, 2017
    Publication date: July 27, 2017
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE
    Publication number: 20160052883
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Application
    Filed: November 2, 2015
    Publication date: February 25, 2016
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Donald W. Landry, Yuli Xie, Yidong Liu, Gangli Gong, Shi-Xian Deng, Kirsten Alison Rinderspacher
  • Potent non-urea inhibitors of soluble epdxide hydrolase
    Patent number: 9175285
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: November 3, 2015
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Donald W. Landry, Yuli Xie, Yidong Lu, Gangli Gong, Shi-Xian Deng, Kirsten Alison Rinderspacher
  • POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE
    Publication number: 20140349368
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Application
    Filed: February 17, 2014
    Publication date: November 27, 2014
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Donald W. Landry, Yuli Xie, Yidong Lu, Gangli Gong, Shi-Xian Deng, Kirsten Alison Rinderspacher
  • POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE
    Publication number: 20140336193
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Application
    Filed: July 23, 2014
    Publication date: November 13, 2014
    Inventors: Donald W. Landry, Shi-Xian Deng, Stevan Pecic, Kirsten Alison Rinderspacher
  • COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITY
    Publication number: 20140275165
    Abstract: The present invention relates to compounds with activity as BACE1 and NF?B modulators, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease. The present invention is also directed to the treatment of diseases related to dysfunction of cell proliferation, the immune system and/or inflammation using such compounds or pharmaceutical compositions containing such candidate compounds.
    Type: Application
    Filed: March 24, 2014
    Publication date: September 18, 2014
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Donald W. Landry, Tae-Wan Kim, Shi-Xian Deng, Gangli Gong, Jeremy C. Hwang, Yuli Xie, Yidong Liu, Kirsten Alison Rinderspacher